CompletedNot Applicable

Inflammation Indıces and Mortality in Adult Crush Syndrome

Turkey (Türkiye)325 participantsStarted 2018-01-01

Plain-language summary

This retrospective observational cohort study aims to evaluate the prognostic value of inflammatory hematological indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune-inflammation value (PIV), in predicting 28-day mortality in adult patients with crush syndrome admitted to the intensive care unit (ICU). Patients aged 18 years and older diagnosed with crush syndrome between January 1, 2018, and September 30, 2025, were included. The primary outcome is 28-day mortality. Secondary outcomes include ICU mortality and in-hospital mortality. The predictive performance of inflammatory indices will be compared with established severity scores such as APACHE II and SOFA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Diagnosis of crush syndrome based on clinical and laboratory findings * Admission to the intensive care unit (ICU) between January 1, 2018 and September 30, 2025 * Availability of complete blood count parameters within the first 24 hours of ICU admission Exclusion Criteria: * Age \<18 years * Incomplete medical records * Missing laboratory data required for calculation of inflammatory indices * Patients discharged or transferred within 24 hours of ICU admission

What they're measuring

28-day All-Cause Mortality

Timeframe: 28 Days

Trial details

NCT IDNCT07433127

SponsorAtaturk University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-10-28

View on ClinicalTrials.gov More Crush Syndrome trials